Department of Neurology

Center for Parkinson Disease and Other Movement Disorders

Dr. Stanley Fahn, Director ,
Clinical research involving most aspects of movement disorders: dystonia and tardive syndromes; clinical pharmacology; genetics of movement disorders; clinical and surgical trials of new therapies for Parkinson disease, dystonia and myoclonus; rating scales; and experimental therapeutics for movement disorders.

Dr. Blair Ford,
Clinical research on Parkinson disease, dystonia, tremor, Tourette syndrome and other movement disorders, including trials of new pharmacological agents, and surgical approaches to Parkinson disease and tremor.

Dr. Steven Frucht,
Clinical research in the phenomenology and experimental therapeutics of movement disorders, including Parkinson disease, myoclonus, dystonia, chorea and tics. Current projects include clinical trials of new treatments for Parkinson disease, evaluation and development of new treatments for myoclonus, and evaluation and treatment of focal task-specific dystonias, including musician’s dystonia.

Dr. Paul Greene,
Clinical phenomenology of movement disorders, experimental therapeutics for Parkinson disease, (including transplantation techniques) and botulinum toxin therapy for dystonia.

Dr. Elan D. Louis,
Clinical, epidemiological, and genetic aspects of essential tremor, Parkinson disease and Huntington disease.

Dr. Cheryl Waters,
Clinical drug trials for Parkinson disease. Clinical research on other parkinsonian syndromes and movement disorders.

Laboratories for The Study of Cellular Mechanisms of Neurodegeneration: The Morris Udall Center for Parkinson Disease Research

Dr. Asa Abeliovich,
The study of the molecular basis of midbrain dopamine neuron function and survival. Midbrain dopamine neurons are thought to play key roles in learned and addictive behaviors and degeneration of these neurons underlies Parkinson disease.

Dr. Robert E. Burke,
Studies of mechanisms of programmed cell death in models of neurodegeneration related to disorders of the basal ganglia, especially parkinsonism. Studies are conducted both in vivo and in vitro, utilizing immunohistochemistry, quantitative morphologic analysis, in situ hybridization, differential display, receptor autoradiography, and enzyme assays.

Dr. William Dauer,
Research focuses on creating and characterizing genetic mouse models of basal ganglia disease, generated through the use of gene targeting. The present emphasis is on the characterizing DYT1 and alpha-synuclein mutants, using anatomic, biochemical and behavioral approaches. Additionally, the laboratory is also involved in strategies that allow region and temporal-specific expression of pathogenic protein in the nervous system.

Dr. Serge Przedborski,
Study of toxin-induced damage to neurotransmitter systems pertinent to movement disorders such as Parkinson disease and Huntington disease. Modes of cell death and free radical-induced toxicity are also investigated. SOD1 mutant transgenic mice serve as a model for amyotrophic lateral sclerosis. Methods include transgenic mice, immunohistochemistry, in situ hybridization, quantitative morphology, receptor binding, HPLC, classical histology.

Dr. David Sulzer,
Study of dopamine synaptic plasticity and its pharmacological manipulation by drugs used for treatment of Parkinson disease and schizophrenia, as well as modulation by intrinsic synaptic proteins. Investigations also include mechanisms of addictive-drugs associated with dopamine systems and cell culture models of catecholamine neurotoxicity and neurodegeneration. Methods include electrophysiology, electrochemistry, HPLC, quantitative microscopy, molecular biology and neuronal cell culture.

Laboratories For The Study Of Motor Control

Drs. John Krakauer,
Pietro Mazzoni,
The neurological mechanisms underlying the initiation and control of reaching movement are studied by kinematic, electromyographic analyses, PET, and fMRI in normal humans and patients with cerebral or cerebellar lesions. Deficits in kinematic control are analyzed following a variety of focal lesions, typically stroke. Recovery and restoration of function are emphasized.

Dr. Seth Pullman,
Clinical neurophysiologic techniques are used to quantify motor disability and study motor control in patients with neurologic disease. These techniques include kinesiologic and EMG methods; reaction and movement time analyses; transcranial magnetic stimulation of the cortex in conjunction with peripheral stimuli; evoked craniofacial and limb evoked motor recovery curves after multiple stimuli; and backaveraging techniques linking EEG to EMG activity. The effects of treatment such as use of intramuscular botulinum toxin injection are also evaluated using physiologic methods. Artificial neural network and engineering techniques are being developed to analyze and quantify movement disorders.

Stroke Center And Neurovascular Center Clinical Research Programs

Dr. Mitchell S. Elkind,
Stroke risk factors and prevention. Focus on different inflammatory markers and infections, such as C. pneumoniae and periodontal disease, as potential causes of atherosclerosis and ischemic stroke. Use of high-resolution duplex doppler ultrasonography as a measure of stroke risk. Clinical trials of neuroprotectants and surgical hemicraniectomy for acute stroke, and antiplatelet and other therapies for stroke prevention.

Dr. Randolph S. Marshall,
Behavioral and physiologic investigation of early hemispheric ischemia in patients undergoing therapeutic carotid balloon test occlusions. Evaluation of visual-spatial dysfunction using behavioral and functional imaging methodologies.

Dr. Jay P. Mohr,
Research is focused on clinical, radiologic and pathologic correlations of clinical stroke syndromes; doppler studies and cerebral hemodynamics of large-artery disease; arteriovenous malformations (AVMs); studies of the course and outcome of stroke and its various subtypes; cardiac and hematologic risk factors of stroke; and modification of stroke outcome by specific therapies tested in multi-center trials.

Dr. Ralph L. Sacco,
Research focuses on stroke prevention and risk factor detection, design and conduct of clinical tnials, and neurological outcomes following stroke. The Northern Manhattan Stroke Study (NOMASS) is an NIH funded cohort study of stroke in the community. Dr. Sacco is also co director of the Neuroepidemiology Training Program.

Dr. Clinton Wright,
Study of the effect of different forms of vascular disease on cognitive impairment and decline in a population-based study.

Cerebral Localizaion Laboratory

Drs. Ronald M. Lazar,
Randolph S. Marshall,
A clinical research unit dedicated to investigation of the behavioral outcomes of strokes and related vascular diseases. Computerized assessment of stroke patients’ behaviors, functional magnetic resonance imaging, superselective arterial amobarbital (Wada) testing, and transcranial Doppler ultrasonography allow measurement of cerebral plasticity with principal focus on the brain’s abilities to compensate for injury.

Basic Research Laboratory

Dr. E. Sander Connolly,
Dr. Augusto Parra,
Mechanisms of ischemic injury. Cellular and molecular neuroprotective mechanisms and new therapeutic strategies.

The H. Houston Meritt Center for Neuromuscular Disorders Muscle Disease Molecular

Dr. Eduardo Bonilla,
Research involving the ultrastructure of membrane systems in normal and diseased human muscle. Procedures utilized involve transmission electron microscopy, immunocytochemistry, and in situ hybridization.

Dr. Mercy Davidson,
Morphological, biochemical, molecular genetic and electrophysiological analyses of mitrochondrial encephalomyopathies using transmitochondrial cybrids, skeletal myoblasts, cardiomyocytes and neuronal cells. Studies of tissue-specific effects of mutations associated with these diseases on normal development and function; and cell culture models for devising potential therapeutic strategies.

Dr. Salvatore DiMauro,
Biochemical and DNA investigations of human metabolic myopathies, including disorders of glycogen metabolism, lipid metabolism, and mitochondrial function.

Dr. Michio Hirano,
Molecular biology of neuromuscular disorders. Positional cloning techniques are applied to autosomal disorders affecting the mitochondrial genome. Investigations of mutations of mitochondrial DNA in human cardiomyopathies.

Dr. Eric A. Schon,
Molecular genetic studies of neuromuscular disorders. Current work includes analysis of respiratory chain genes (cytochrome c oxidase) mutations of mitochondrial DNA in human disease, and in vitro gene therapy.

Muscle And Nerve Pathology Laboratory

Dr. Arthur P. Hays,
Morphologic studies of diabetes and other neuropathies and motor neuron diseases.

Eleanor and Lou Gehrig MDA/ALS Center

Dr. Hiroshi Mitsumoto, Director,
The Center provides a multidisciplinary team approach for patients with ALS and their families. Comprehensive services include access to medical and psychosocial management, innovative therapeutic clinical trials, basic and clinical research, and expertise in palliative and biomedical care.

Dr. Paul Gordon,
Neuromuscular clinical research, ALS clinical trials and electromyography.

Dr. Petra Kaufmann,
Muscular dystrophies, mitochondrial myopathies, other genetic diseases of muscle.

Clinical Neurophysiology Laboratories Clinical Neuromuscular Physiology Center

Dr. Clifton L. Gooch,
Understanding diseases of nerve and muscle through electrophysiologic analysis of peripheral nervous system function in patients. Active areas of research include motor unit number estimation in amyotrophic lateral sclerosis (ALS) and related diseases; electrophysiologic assessment of experimental drug effects; single fiber electromyography and its applications in humans and animal models; quantitative electromyography in myopathic and neuropathic disease; development and application of novel electrophysiologic computerized techniques in EMG; and innovative electrophysiologic techniques for clinical and research applications. The laboratory also provides clinical diagnostic services for a wide and varied population of both inpatients and outpatients at the New York-Presbyterian Hospital and the Neurological Institute.

Clinical Autonomic Dysfunction Laboratory

Dr. Louis H. Weimer,
Clinical evaluation of central and peripheral causes of dysautonomia and autonomic failure, including autonomic neuropathy, multiple system atrophy, and orthostatic intolerance. Techniques include cardiovascular reflex testing, heart rate variability, tilt-table testing, power spectral analysis, and sudomotor estimation. Quantification of small somatic pain and temperature nerve fiber function in peripheral neuropathy and selective small fiber neuropathy.

EEG And Evoked Potential Laboratories

Dr. Ronald G. Emerson,
Generator sources of evoked potentials; sensory processing by the central nervous system; evoked potentials in neurological disorders; technological and systems development. Dipole models of epileptiform discharges; patterns of seizure propagation.

Comprehensive Epilepsy Center

Dr. Frank Gilliam, Director, Comprehensive Epilepsy Center,
Clinical and translational research of most therapeutic techniques in epilepsy, as well as comorbid conditions effects on health outcomes in epilepsy; the neurobiology of depression in epilepsy.

Clinical Research

Dr. Carl W. Bazil,
Investigational trials of novel anticonvulsant drugs; relationship between neurological diseases (especially epilepsy) and sleep; effects of anticonvulsant drugs on sleep and sleep disorders; outcome of epilepsy surgery.

Dr. Hyumni Choi,
Dr. Lawrence J. Hirsch,
Outcomes of epilepsy surgery. Continuous EEG monitoring in NICU patients. Clinical phenomenology and clinical-electrographic correlation studies of non-convulsive status epilepticus. Clinical pharmacology of antiepileptic drugs.

Dr. Steven C. Karceski,
New approaches to the surgical treatment of extratemporal localization-related epilepsies. Treatment options and decision making. Comparative value of different antiepileptic drug regimens.

Dr. Alison Pack,
The treatment of women with epilepsy. The treatment of adolescents with epilepsy. Bone and reproductive health in persons with epilepsy.

Dr. Stanley Resor,
Dr. Tina Shih,
Socioeconomic disparities, patient outcomes research in epilepsy.


Dr. W. Allen Hauser,
Neuroepidemiology of seizures and epilepsy syndromes with specific interests in identifying and quantitating risk factors for seizure occurrence, prognosis, and the consequences of head trauma. Epidemiology of status epilepticus.

Dr. Dale Hesdorffer,
Studies of the association between MRI-detected brain abnormalities and development among children with febrile seizures. Studies of the impact of acute management of severe brain injury on outcomes (in collaboration with the Brain Trauma Foundation). Studies of medical comorbidity associated with epilepsy.

Dr. Ruth Ottman,
Family and genetic studies of epilepsy. Identification of gene defects in relation to seizure/epilepsy phenotypes and seizure susceptibility. Linkage analysis and delineation of susceptibility genes for human epilepsy.

Dr. Melodie Winawer,
Family and genetic studies of epilepsy. Problems in phenotype definition.

Basic Epilepsy Research

Dr. Helen Scharfman,
Electrophysiological and neuroanatomical studies in experimental models of epilepsy and epileptogenesis. Mechanisms of epileptic brain damage and functional consequences of brain lesions. Physiological effects of growth factors and neurotrophins. Neurogenesis as a consequence of seizures and its role in epileptogenesis.

Dr. Guy M. McKhann, II,
Roles of astrocytes in epilepsy; studies of glia-neuron interactions.

Aging and Dementia

This group provides in-patient consultation services for patients with cognitive and behavioral disorders and staffs the Memory Disorders Clinic at the Psychiatric Institute. Residents are encouraged to elect rotations on this service. Research interests in behavioral disorders and dementia primarily focus on degenerative diseases such as Parkinson disease, Alzheimer disease, Huntington disease and stroke. Neurologic, psychiatric and neuropsychologic functions are assessed. Current projects include studies of dementia in Parkinson disease, use of brain imaging in dementia, clinical trials and epidemiology of Alzheimer disease and related disorders; natural history of HIV; cognitive performance in children with complex metabolic disorders. Aging and dementia rounds are held weekly at Columbia-Presbyterian Medical Center and monthly at Harlem Hospital Center. The research activities of the Division of Aging and Dementia are integrated closely with those of the Sergievsky Center, and all divisional faculty hold appointments in the Sergievsky Center.

Dr. Karen S. Marder, Director,
Investigations of genetic influences in families of probands with early-onset compared to late-onset Parkinson disease. Multicenter investigation of risk factors for the development of dementia in HIV. Clinical trials of new therapeutic agents in Huntington disease. Longitudinal study of subjects at risk for developing Huntington disease.

Field work and clinical and basic research utilizing an extended kindred with Huntington disease living in Venezuela, including genotype/phenotype analyses. The Huntington Disease Center of Excellence provides experience in clinical care, psychotherapy and genetic counseling. Clinical trial of Coenzyme Q10 and remacemide in Huntington disease. Activities relating to the ethical, legal and social implications of the Human Genome Project.

Dr. Mark W. Albers,
Laboratory research mapping the circuits that underlie odor discrimination in mice using genetic markers of olfactory neurons and genetic sensors of neuronal activation; cellular and molecular changes in these neurons induced by experience-dependent learning. Studies using transgenic models of Alzheimer disease to study how olfactory stimuli are processed.

Dr. Karen L. Bell,
Development of new clinical treatments for Alzheimer disease. Currently Conducting research for the prevention of Alzheimer disease in individuals with mild cognitive impairment. Other research interests include understanding barriers that minorities face in receiving clinical care for dementia and cognitive loss, and developing mechanisms to recruit minorities into clinical research.

Dr. Lucien Coté,
Epidemiology and genetics of Parkinson disease. Studies of depression and dementia in Parkinson disease.

Dr. Laurence C. Honig,
Clinical studies of Alzheimer disease. Clinical-pathological correlations in Alzheimer disease and related dementias.

Dr. Jennifer Manly,
Epidemiology and genetics of Parkinson disease. Studies of depression and dementia in Parkinson disease.

Dr. Richard Mayeux,
see Sergievsky Center

Dr. Scott Small,
Correlations of memory and changes in the hippocampal formation using functional magnetic resonance imaging in normal aging and in Alzheimer disease.

Dr. Nancy S. Wexler,
Genetic and field studies of Huntington disease in Maricaibo, Venezuela.

The G.H. Sergievsky Center

The Gertrude H. Sergievsky Center uses traditional and genetic epidemiologic approaches to the study of neurologic disorders. The areas of major interest include adverse reproductive outcomes, epilepsy and seizure disorders, degenerative diseases of the nervous system, developmental disorders of the nervous system, and neurological disorders of major public health impact. Allied disciplines in the health sciences include biostatistics, human genetics, neurology, obstetrics, pediatrics, physiology, psychiatry, psychology, and social sciences. The faculty of a federally funded training program in neuroepidemiology are located primarily within the Sergievsky Center.

Dr. Richard Mayeux,
Director, G.H. Sergievsky Center and Co-Director, Taub Institute for Alzheimer Disease.

Epidemiology and Genetics of Alzheimer Disease and Parkinson Disease

Dr. Steven M. Albert,
Epidemiologic studies investigating the cognitive basis of functional competency of patients with HIV, Alzheimer disease and ALS. Ongoing studies of disease-related changes contributing to patient quality of life, nursing home placement, hospitalization and home care costs.

Dr. Jennie Kline,
Epidemiology of spontaneous abortion; chromosomal disorders including trisomy; autism and other selected developmental disorders.

Dr. Ruth Ottman,
Neuroepidemiology and genetic studies of epilepsy, Parkinson disease and ALS.

Dr. Nicole Schupf,
Genetic epidemiology of Down syndrome and Alzheimer disease.

Dr. Zena Stein,
Epidemiology of mental retardation and developmental brain diseases.

Dr. W. Allen Hauser,
Associate Director (see Neuroepidemiology under the Comprehensive Epilepsy Center).

Dr. Karen S. Marder,
(see Aging and Dementia)

Dr. Karen L. Bell,
(see Aging and Dementia)

Dr. Laurence C. Honig,
Dr. Elan D. Louis,
(see Movement Disorders)
Dr. Scott Small,
(see Aging and Dementia)

Dr. Yaakov Stern, Head, Cognitive Neuroscience,
Experimental and neuroimaging approaches to cognitive issues in normal aging and diseases of the aging brain (including Alzheimer, Parkinson and Huntington diseases). Current experimental cognitive studies include: source memory, working memory, priming, and the interplay between explicit recollection and familiarity in normal aging; basic timing mechanisms in normal aging and Parkinson disease; language and working memory in Alzheimer disease; and effects of literacy, education, ethnicity and acculturation on neuropsychological task performance in cognitive neuroimaging. Cognitive neuroimaging studies include: network changes in mediating recognition and working memory and cognitive reserve in normal aging and Alzheimer disease (H2 15O PET and fMRI); age priming in young adults and normal aging (ER-fMRI) executive function in normal aging and Huntington disease (fMRI), and effects of estrogen on recognition and source memory in elderly women (ERP).

Pediatric Neurology: The Colleen Guilin Laboratories For Pediatric Neurology Research

Dr. Marc C. Patterson, Director,
Pathophysiology of Niemann-Pick Disease, Type C. Therapeutic trials of Coenzyme Q10, and glucosylceramide synthase inhibition in Niemann-Pick, Type C. Diagnosis and management of congenital disorders of glycosylation. Studies of the neurobiological basis of autistic spectrum disorders.

Dr. Darryl C. De Vivo,
Biochemical and molecular studies of inherited and acquired metabolic diseases that affect the developing nervous system and muscular system. Research focuses on defects of oxidative metabolism and the molecular basis of glucose transporter deficiency syndromes. Clinical trials in mitochondrial encephalomyopathies.

Dr. Claudia Chiriboga,
Studies of neurological, behavioral and psychological outcomes in children with intrauterine exposure to cocaine. Neuro-developmental outcomes of brain injuries associated with prematurity.

Dr. Linda Leary,
Pediatric epilepsy and the role of epilepsy surgery in children. Studies of subtraction ictal SPECT and interictal PET scans in children with epilepsy being considered for surgery. Studies of the association of malformations of cortical development and intractable epilepsy. Age-dependent epileptic syndromes of childhood.

Dr. Arthur Mandel,
Disorders of cerebral energy failure, using functional magnetic resonance imaging.

Dr. Juan Pascual,
Studies of ion channel structure, function and pharmacological modification in molecular excitability disorders, including genetic myopathies, neurotoxicity, epilepsy and arrhythmias.

Critical Care

Dr. Stephan A. Mayer, Director,
Dr. Christopher Commichau
Dr. Brian-Fred Fitzsimmons
Dr. Augusto Parra

Clinical trials and outcomes research related to intracerebral and aneurysmal subarachnoid hemorrhage. Clinical trials of hypothermia and hemicraniectomy for acute ischemic stroke. Quality of life and cognitive function after aneurismal subarachnoid hemorrhage. Other research interests include neurogenic cardiac arrhythmias, status epilepticus and end-of-life care.


Dr. Casilda Balmaceda,
Studies of primary brain tumors including gliomas, oligodendrogliomas, lymphomas and pineal tumors; leptomeningeal tumors; paraneoplastic syndromes. Multicenter clinical trials of new therapeutic agents.

Rose Lai, M.D.,
The molecular epidemiology of brain tumors. Population-based studies to elucidate different genetic polymorphisms and their role in the pathogenesis of brain tumors, especially glioma. Using metabolic imaging techniques to identify molecular markers in brain tumors and predict responsiveness to treatment.

Steven Rosenfeld, M.D., Ph.D.,
Director, NYPH Brain Tumor Center
Novel ways of pharmacologically-blocking brain tumor growth and invasiveness by targeting the molecular motors that drive mitosis and cell motility.